Focusing and Sustaining the Antitumor CTL Effector Killer Response by Agonist Anti-Cd137 mAb

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.1506357112
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

Enhanced T-Cell-Independent Antitumor Effect of Cyclophosphamide Combined With Anti-Cd40 mAb and CpG in Mice

Journal of immunotherapy (Hagerstown, Md. : 1997)
Cancer ResearchAllergyImmunologyPharmacology
2011English

4-1bb (CD137) Ligand Enhanced Anti-Tumor Immune Response Against Mouse Forestomach Carcinoma in Vivo

Cellular and Molecular Immunology
Infectious DiseasesMedicineAllergyImmunology
2008English

Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells

Gastroenterology
HepatologyGastroenterology
2016English

Combination of 4-1bb Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model

Cancer immunology research
Cancer ResearchImmunology
2014English

Cutting Edge: Rapid in Vivo CTL Activity by Polyoma Virus-Specific Effector and Memory CD8+ T Cells

Journal of Immunology
AllergyImmunology
2003English

Cancer Immunotherapy With Immunomodulatory Anti-Cd137 and Anti-Pd-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

Cancer Discovery
Oncology
2015English

A Developed STING Agonist Has Systemic Antitumor Activity

Cancer Discovery
Oncology
2018English

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

Journal of Immunology
AllergyImmunology
2002English

NOP Receptor Mediates Anti-Analgesia Induced by Agonist–antagonist Opioids

Neuroscience
Neuroscience
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy